{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-009996","form_type":"8-K","ticker":"AZTR","cik":"0001701478","company_name":"Azitra, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.388479+00:00","generated_at":"2026-05-21T16:33:45.125386+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Azitra Q1 net loss $3.1M, cash $3.2M; secures up to $20M funding from Alumni Capital","bullets":["Net loss $3.1M for Q1 2025 vs $2.9M in Q1 2024; R&D $1.3M, G&A $1.9M.","Cash $3.2M as of March 31, 2025; signed up to $20M purchase agreement with Alumni Capital LP.","Closed two public offerings raising $2.2M.","ATR-12 Phase 1b initial safety data expected 1H 2025; topline data by YE 2025.","ATR-04 Phase 1/2 first patient dosing expected 1H 2025; ASCO poster accepted."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-009996","json":"https://secwatch.observer/filing/0001641172-25-009996.json","markdown":"https://secwatch.observer/filing/0001641172-25-009996.md","text":"https://secwatch.observer/filing/0001641172-25-009996.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701478/000164117225009996/0001641172-25-009996-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701478/000164117225009996/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T16:33:45.125386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}